Premier Alternatives

BreezeBio

South San Francisco, CA · Founded 2016 · Privately Held (backing)

Developer of curative therapies designed for current gene therapy delivery challenges by systematically screening its proprietary nanoparticle library. BreezeBio is based in South San Francisco, CA and was founded in 2016. Its last reported valuation was $234 million in Feb 2026. It has raised $117 million.

Last reported valuation
$234.0M
Oct 2026
Priced at
—
Total raised
$117.0M
Last round
—

BreezeBio key facts

as of Oct 2026
  • Developer of curative therapies designed for current gene therapy delivery challenges by systematically screening its proprietary nanoparticle library.
  • BreezeBio is valued at approximately $234.0M as of Oct 2026 (last reported valuation).
  • It has raised $117.0M; the latest was Later Stage VC ($60.0M) in Feb 2026.
  • Notable investors include US National Science Foundation, Sequoia Capital, KB Investment, Korea Investment Partners, Qiming Venture Partners — 39 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$234.0M

BreezeBio's last reported valuation, Feb 2026. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of BreezeBio with a free account
  • ·The complete investor list: 39 names
  • ·Watch BreezeBio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

BreezeBio funding rounds

No rounds on record

No funding rounds for BreezeBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

BreezeBio valuation

BreezeBio's last reported valuation was $234 million in Feb 2026. No priced round, secondary trade or fund mark has surfaced since.

BreezeBio investors

39 investors are on record for BreezeBio, including US National Science Foundation, Sequoia Capital, KB Investment and Korea Investment Partners. By type, the record holds 12 venture capital firms and 1 hedge fund.

About BreezeBio

Developer of curative therapies designed for current gene therapy delivery challenges by systematically screening its proprietary nanoparticle library. The company's tool makes therapeutic gene editing possible and is easier to use, faster, and more accurate than previous gene-editing techniques, and also has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases, and also provides safer and more efficient delivery to target tissues.

Sector
Healthcare
HQ
South San Francisco, CA, United States
Founded
2016
Employees
63
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.